Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Paul B. Chapman, Grant A. McArthur, Keith T. Flaherty et al.|Annals of Oncology|2017

Cited by 258